A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients.

被引：0
|
作者：
Burckart, G. [1 ]
Cavaille-Coll, M. [2 ]
Duong, A. [3 ]
Hothem, L. [4 ]
Albrecht, R. [2 ]
机构：
[1] US FDA, Off Clin Pharmacol, Off Translat Sci, CDER, Silver Spring, MD USA
[2] US FDA, Div Transplant & Opthalmol Prod, Off New Drugs, CDER, Silver Spring, MD USA
[3] Tauro Univ, New York, NY USA
[4] Univ N Carolina, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2018年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B245
引用
收藏
页码：714 / 714
页数：1
相关论文
共 44 条
  • [21] Pediatric to adult transition in solid organ transplant recipients: A systematic review of existing transition programs.
    Yerigeri, Shivani
    Satariano, Matthew
    Pape, Lars
    Johnson, Jonathan N.
    Marks, Stephen D.
    Twombley, Katherine E.
    Doshi, Kush
    Oh, Jun
    Mcculloch, Mignon
    Esquivel, Carlos O.
    Raina, Rupesh
    TRANSPLANTATION, 2024, 108 (9S)
  • [22] Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020
    Green, Francis G.
    Park, Kyunghun
    Burckart, Gilbert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 : S28 - S35
  • [23] INFLUENCE OF HEPATITIS C VIRUS INFECTION ON THE DEVELOPMENT OF INTERSTITIAL FIBROSIS AND TRANSPLANT GLOMERULOPATHY IN PEDIATRIC RENAL TRANSPLANT PATIENTS.
    Ozdemir, B. Handan
    Baskin, E.
    Ozdemir, F. Nurhan
    Moray, G.
    Haberal, M.
    PEDIATRIC TRANSPLANTATION, 2017, 21 : 39 - 39
  • [24] A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007–2013
    Gunter F. Egger
    Gerold T. Wharton
    Suzanne Malli
    Jean Temeck
    M. Dianne Murphy
    Paolo Tomasi
    Therapeutic Innovation & Regulatory Science, 2016, 50 : 639 - 647
  • [25] Juvenile Animal Studies and Pediatric Drug Development Retrospective Review: Use in Regulatory Decisions and Labeling
    Tassinari, Melissa S.
    Benson, Kimberly
    Elayan, Ikram
    Espandiari, Parvaneh
    Davis-Bruno, Karen
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (04) : 261 - 265
  • [26] Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients
    Cangemi, Michela
    Montico, Barbara
    Fae, Damiana A.
    Steffan, Agostino
    Dolcetti, Riccardo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [27] A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007-2013
    Egger, Gunter F.
    Wharton, Gerold T.
    Malli, Suzanne
    Temeck, Jean
    Murphy, M. Dianne
    Tomasi, Paolo
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (05) : 639 - 647
  • [28] Drug-Drug Interactions Between Antiretroviral and Immunosuppressive Agents in HIV-Infected Patients After Solid Organ Transplantation: A Review
    van Maarseveen, Erik M.
    Rogers, Christin C.
    Trofe-Clark, Jennifer
    van Zuilen, Arjan D.
    Mudrikova, Tania
    AIDS PATIENT CARE AND STDS, 2012, 26 (10) : 568 - 581
  • [29] Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: Review of the literature
    Arns, Wolfgang
    Cibrik, Diane M.
    Walker, Rowan G.
    Mourad, Georges
    Budde, Klemens
    Mueller, Edgar A.
    Vincenti, Flavio
    TRANSPLANTATION, 2006, 82 (08) : 1004 - 1012
  • [30] Development of a Web-based, computerized and patient-specific pediatric emergency drug card for hospitalized patients.
    Veltri, MA
    Matlin, C
    Lehmann, CU
    PHARMACOTHERAPY, 2004, 24 (10): : 1478 - 1478
12345